Different refractive errors in triplets with retinopathy of prematurity treated with bevacizumab

J Pediatr Ophthalmol Strabismus. 2012 Aug 7:49 Online:e41-3. doi: 10.3928/01913913-20120731-03.

Abstract

The authors report refractive errors possibly resulting from intravitreal bevacizumab injection. Triplet A presented with stage 3 retinopathy of prematurity, was treated with intravitreal bevacizumab, and high refractive errors were noted. Triplet B presented with stage 2 retinopathy of prematurity in the right eye and stage 3 retinopathy of prematurity in the left eye, which regressed spontaneously. Triplet C presented with stage 2 retinopathy of prematurity in the right eye and stage 3 retinopathy of prematurity in the left eye, which were treated with intravitreal bevacizumab.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Bevacizumab
  • Female
  • Gestational Age
  • Humans
  • Hyperopia / chemically induced*
  • Hyperopia / diagnosis
  • Infant, Newborn
  • Infant, Premature
  • Infant, Very Low Birth Weight
  • Intravitreal Injections
  • Male
  • Myopia / chemically induced*
  • Myopia / diagnosis
  • Retinopathy of Prematurity / classification
  • Retinopathy of Prematurity / drug therapy*
  • Triplets*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab